头孢吡肟
阿兹屈南
头孢他啶/阿维巴坦
头孢菌素
微生物学
美罗培南
阿维巴坦
生物
头孢他啶
大肠杆菌
碳青霉烯
亚胺培南
医学
抗生素
铜绿假单胞菌
细菌
抗生素耐药性
遗传学
基因
生物化学
作者
Christophe Le Terrier,Patrice Nordmann,Chloé Buchs,Laurent Poirel
摘要
ABSTRACT The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and to cefiderocol. A large series of E. coli recombinant strains producing broad-spectrum β-lactamases was evaluated. While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.
科研通智能强力驱动
Strongly Powered by AbleSci AI